A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
Presented By Patrick Wen at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
Intergroup trial CALGB 80101
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A prospective randomized trial
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Long-Term versus Short-Term Androgen Deprivation Combined with High-Dose Radiotherapy for Intermediate and High Risk Prostate Cancer: Preliminary Results.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
Presented By Michael Overman at 2016 ASCO Annual Meeting
 Exemplary Care  Cutting-edge Research  World-class Education  Title of the paper Your name Critical Care Medicine School of Medicine University of.
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.
Sample Journal Club Your Name Here.
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Presented By James Hill at 2016 ASCO Annual Meeting
A cura di Filippo de Marinis
CCO Independent Conference Highlights
PRESENTER NAME Waikato Cardiothoracic Unit Journal Club
Securing the cure in resectable lung cancer
Presented By Michael Lee at 2016 ASCO Annual Meeting
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Presented By Jason Fangusaro at 2017 ASCO Annual Meeting
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
But how to treat those with positive SLNB? Results and Discussion
PCSK9 Inhibitors Post-CVOTs
The Safety and Efficacy of Full vs
New Treatments for CTEPH
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
Aspirin and Cardioprevention in 2018
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.
Elevated Admission Plasma Glucose Following ACS
Main inclusion criteria)
Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial  Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
My PAH Patient.
Presentation transcript:

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Disclosures Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Background Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Psychostimulants and Primary Brain Tumors Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Methods Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Elgibility Criteria Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Statistics Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Statistics Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Consort Diagram Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Patient Characteristics Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Toxicity Attributed to Treatment Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Primary Endpoint Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Secondary Endpoint Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Secondary Endpoint Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Secondary Endpoint Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Conclusions Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Discussion Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Acknowledgments Presented By Eudocia Lee at 2014 ASCO Annual Meeting

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.